Enflicoxib for the long-term management of canine osteoarthritis-External validation of a population pharmacokinetic model in dogs with osteoarthritis.

ABSTRACT:

Introduction

Enflicoxib is a cyclooxygenase-2 (Cox-2) selective non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation in canine osteoarthritis (OA) and in soft and orthopedic surgery. Canine OA is a chronic progressive disease that requires long-term therapy.

Methods

The suitability of enflicoxib for its long-term use was assessed by analyzing the concentrations determined in plasma samples from dogs included in a field clinical study using a previously established population pharmacokinetic (popPK) model. One hundred and nine client-owned dogs with OA of different breeds, ages, and weights were enrolled and treated with enflicoxib weekly for 6 months at the recommended dose. Safety was assessed clinically and by repeated blood and

SUBMITTER: Cendros JM 

PROVIDER: S-EPMC12505664 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature